Novo Nordisk Launches Obesity Medicine Wegovy® (Semaglutide 2.4mg) (MAL24126014AZ) in Malaysia: A Key Advancement in the Fight Against Obesity and Cardiovascular Risks for People Living with Overweight

Recently, I attended the launch event where Novo Nordisk announced the availability of Wegovy® (semaglutide 2.4 mg) (MAL24126014AZ) in Malaysia. The treatment is introduced as an adjunct option for adults living with obesity and overweight who have at least one weight-related comorbidity. The launch comes at a critical time, as findings from the National Health and Morbidity Survey (NHMS) 2023 show that nearly 54.4% of Malaysian adults are classified as living with overweight or obesity.

Obesity is a chronic disease linked to more than 200 possible health complications and is often considered a “gateway” condition to serious illnesses such as type 2 diabetes and cardiovascular disease. These complications can have a profound effect on both life expectancy and overall quality of life.

Wegovy® (semaglutide 2.4 mg) is a once-weekly injectable treatment that mimics the natural gut hormone GLP-1, which is released after eating. By acting on areas of the brain that control appetite and cravings, it offers support for individuals who struggle with weight management.

The treatment is indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management, including weight loss and weight maintenance, in adults with an initial body mass index (BMI) of ≥30 kg/m², or ≥27 kg/m² to <30 kg/m² when at least one weight-related comorbidity is present, such as dysglycaemia (prediabetes or type 2 diabetes mellitus), hypertension, dyslipidaemia, obstructive sleep apnoea, or cardiovascular disease. Clinical studies show that Wegovy® can deliver weight loss of 20% or more in people living with obesity. In addition, semaglutide has been shown to reduce fat mass to a greater extent than lean body mass, supporting effective and sustainable quality weight loss.

Dr. Praful Chakkarwar, General Manager of Novo Nordisk Malaysia, stated, “Today marks a pivotal moment in our commitment to transforming the healthcare landscape in Malaysia. With Wegovy®, we are introducing an effective weight loss medication that supports patients in their health journeys. This innovative treatment aims to redefine our approach to obesity management and sits at the centre of a broader, long-term strategy: local clinical research, corporate partnerships, community toolkits, internal initiatives and public platforms such as Truth About Weight.”

Professor Dr. Rohana Abdul Ghani, Consultant Endocrinologist & President of the Malaysian Obesity Society (MYOS), highlighted the complex nature of obesity, emphasising that it is far more than a matter of willpower or lifestyle choices. “Obesity is a biological, behavioural, and environmental condition, and not simply the result of lack of discipline or poor lifestyle choices. Unfortunately, it is often misunderstood, leading to self-blame and stigma among those affected. These emotional and social barriers can make effective weight management even more challenging. By combining medical therapy with education, empathy, and multidisciplinary care, we can promote a holistic approach, such as one that fosters resilience, reduces stigma, and encourages individuals to achieve sustained health improvements.” 

Emeritus Professor Dr. Chan Siew Pheng, Honorary Consultant Endocrinologist, emphasised the importance of a collaborative approach in obesity management, stating, “Effective management of obesity involves contribution from a multidisciplinary team of healthcare professionals, including physicians, nutritionists nurse educators, physiotherapists, and mental health professionals to deliver a holistic and integrated care that meets the diverse needs of these individuals. It’s essential to address the common misunderstanding that obesity is merely a lifestyle condition, which can lead to self-blame among individuals struggling with their weight. It's also important to recognise that when individuals lose weight, metabolic adaptations occur that tend to cause weight to regain, reinforcing that this journey requires a more in-depth understanding of the body's responses to weight loss. By integrating medication with personalised dietary and lifestyle interventions, we can significantly improve patient outcomes and support individuals on their health journey. 

Dato’ Sri Dr. Azhari Rosman, Senior Consultant Cardiologist/Director of Customer Experience Department, stressed the direct connection between obesity and cardiovascular health, noting, “The link between obesity and heart disease is one we cannot afford to ignore. Implementing effective obesity management strategies is essential for improving overall health outcomes.”

Novo Nordisk Malaysia continues its commitment to improving the lives of people living with chronic conditions and the challenges that come with them. With a focus on building a healthier future for millions of Malaysians, the company strives to help shape a new era of care.